Join Cliff Stocks, Pat Gray, Mike Gallatin & More Nov. 27 for ‘The Icos Impact’

Icos was once the great hope for Seattle biotech. Founded in 1990 with investment from Bill Gates and inspirational leadership from George Rathmann, it went on over the next 15 years to assemble a team of 700 employees and create a $1 billion molecule.

But as anyone in business more than a few years knows, nothing lasts forever, and Icos didn’t either. It was acquired for $2.3 billion by Eli Lilly in 2007, which picked up the crown jewel of tadalafil (Cialis) and sent most of the workforce packing. That wasn’t good news for a lot of people who enjoyed good, steady work at Icos with colleagues they enjoyed working with. But it did also free up a lot of talented people who have moved on to other high-impact things around the Seattle biotech community.

Given the historic importance of Icos and its alumni to the growth and future of Seattle biotech, I’m excited to bring together many of the veterans for a special reunion event called “The Icos Impact.” This event will be held the evening of Nov. 27 at the Institute for Systems Biology’s headquarters in South Lake Union. This is modeled after a hit event we did last December for Immunex alumni, who came out in droves to re-connect with old friends and hear what’s new and interesting in Seattle biotech.

We have a great lineup of Icos alumni who have agreed to share some fun and revealing stories about their experiences at Icos in the ‘90s and 2000s. Here’s who you can expect to hear from:

Cliff Stocks, CEO, Theraclone Sciences

Patrick Gray, Scientific Fellow, Omeros

Mike Gallatin, Senior Advisor, Frazier Healthcare Ventures

Susan Sullivan, VP of project management, CMC Biologics

David McElligott, chief scientific officer, Accelerator

Gary Wilcox, CEO, Cocrystal Discovery

Stephanie Florio, scientist, Infectious Disease Research Institute

I’m looking forward to this being one of the most fun events we do all year in Seattle biotech. It’s a chance to re-connect with a lot of familiar faces, and maybe learn a few things about biotech of the past that could be useful in the future. So get your tickets early, and mark your calendars for Nov. 27. See you there at the ISB.

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.